BPC 157 enhances function of immunological effector cells in mice
FDA requires precise characterization of drug productsdifficult for complex peptide mixtures derived from animal tissue
This is supported by preclinical and some early clinical data
Contact your healthcare provider if you experience: Severe or persistent abdominal pain Continuous vomiting or dehydration Severe constipation lasting for several days Signs of low blood sugar levels (dizziness, confusion, lightheadedness, sweating, or rapid heartbeat) Allergic or hypersensitivity reaction (Symptoms of hypersensitivity reaction are skin rash, itching, urticaria (hives), flushing, shortness of breath, swelling of face, lips, and tongue, redness, sneezing, nasal congestion, watery eyes, cough, wheezing, chest tightness, dizziness, vomiting, abdominal pain, rapid heartbeat, and low blood pressure
However, 5-Amino-1MQ is classified as a small-molecule research compound
The Wolverine protocol is a two-peptide recovery treatment combining BPC-157 (Body Protection Compound-157) and TB-500 (a synthetic fragment of Thymosin Beta-4)
